Nivagen Pharmaceuticals, a Sacramento, CA-based specialty pharmaceuticals company, closed a $16m equity financing round.
The round was led by Telegraph Hill Partners with participation from existing investors.
The company intends to use the funds for internal development and acquisition of additional generic and branded drugs to broaden its product portfolio.
Led by Mr. Jay Shukla, CEO, Nivagen is a specialty pharmaceuticals company engaged in the development and sale of difficult to formulate generic and branded prescription drugs for the North American market. The company is building a broad portfolio of drug products by developing, acquiring, and in-licensing unique formulations to serve the needs of its customers and is also exploring strategies to develop or acquire manufacturing facilities in the United States to alleviate supply disruptions and accelerate time to market for its pipeline products.
FinSMEs
20/05/2020